Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors
Ryan A. Wilcox(University of Michigan), Lieping Chen(Yale Cancer Center), Scott E. Strome(Northwestern Medicine Lake Forest Hospital), Dallas B. Flies(Mayo Clinic in Arizona), Aaron J. Johnson(Mayo Clinic), Larry R. Pease(Mayo Clinic), Andrei I. Chapoval(Human Genome Sciences (United States)), Gefeng Zhu(Mayo Clinic in Arizona), Koji Tamada(Yamaguchi University)
Cited by 260
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
|Nature Medicine|2002|5.1k
Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
|Journal of Clinical Investigation|2015|1.4k
B7-H3: A costimulatory molecule for T cell activation and IFN-γ production
|Nature Immunology|2001|1k
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
|Proceedings of the National Academy of Sciences|2004|767